Triheptanoin use for severe neonatal cardiomyopathy secondary to mitochondrial trifunctional protein deficiency: a first report

Cardiol Young. 2025 Jan;35(1):218-220. doi: 10.1017/S1047951124026386. Epub 2025 Jan 9.

Abstract

Mitochondrial trifunctional protein deficiency is a long-chain fatty acid disorder that may include manifestations of severe cardiomyopathy and arrhythmias. The pathophysiology for the severe presentation is unclear but is an indicator for worse outcomes. Triheptanoin, a synthetic medium chain triglyceride, has been reported to reverse cardiomyopathy in some individuals, but there is limited literature in severe cases. We describe a neonatal onset of severe disease whose clinical course was not improved despite mechanical support and triheptanoin.

Keywords: Cardiomyopathy; ECMO; long-chain fatty acid oxidation disorder; newborn screen; trifunctional protein deficiency; triheptanoin.

Publication types

  • Case Reports

MeSH terms

  • Cardiomyopathies* / etiology
  • Echocardiography
  • Humans
  • Infant, Newborn
  • Lipid Metabolism, Inborn Errors* / complications
  • Mitochondrial Myopathies / complications
  • Mitochondrial Trifunctional Protein / deficiency
  • Rhabdomyolysis / etiology
  • Triglycerides* / blood

Substances

  • Mitochondrial Trifunctional Protein
  • Triglycerides
  • triheptanoin

Supplementary concepts

  • Trifunctional Protein Deficiency With Myopathy And Neuropathy